サンプル依頼リスト カート
  • English
  • Korean
表紙：プロテオミクスの世界市場-2023年～2030年
市場調査レポート
商品コード
1352181

プロテオミクスの世界市場-2023年～2030年

Global Proteomics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
プロテオミクスの世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

プロテオミクス市場の動向は、技術進歩や調査研究の増加に起因する研究の上昇を示しています。さらに、承認された機器の利用可能性の上昇、市場におけるがん患者数の増加、研究開発の増加によるプロテオミクスへの応用の高まりが、プロテオミクス市場規模を押し上げています。

この分野での進歩の高まりにより、北米からの治療需要が伸びています。Thermo Fisher Scientific Inc.、Danaher、Agilent Technologies, Inc.、Merck KGaAのような主要な競合企業が市場で活発に活動しているため、市場は今後成長すると思われます。

ダイナミクス

がんのバイオマーカーに関する調査件数の増加がプロテオミクス市場の成長を牽引

プロテオミクス技術は現在、分子医学、特にバイオマーカーの同定に広く応用されています。プロテオミクスは、体液中の世界なタンパク質プロファイリングを評価することで、重要な疾患特異的バイオマーカーを見つけることができます。健康なサンプルと疾患に罹患したサンプルのタンパク質発現プロファイルを対比することで、プロテオミクスの発現はバイオマーカーの同定を可能にします。バイオマーカーを見つける最も簡単な方法は2D-PAGEで、腫瘍組織や体液を含む健康なサンプルと病気のサンプルのタンパク質プロファイルを比較します。

疾患特異的バイオマーカーは、その情報から、予後バイオマーカー、診断バイオマーカー、治療予測バイオマーカーに分類されます。疾患関連バイオマーカーとして作用する可能性のあるタンパク質や、疾患の経過に関与する可能性のあるタンパク質は、プロテオミクスを使って見つけることができます。質量分析によって発見されたバイオマーカーは、バイオインフォマティクス解析によって処理され、他の集団で再現される必要があります。

残念なことに、プロテオミクス技術を利用して明らかになったバイオマーカーのうち、関心が高まり、治験の負担が重くなり、かなりのレベルの論文が発表されたにもかかわらず、最終的にバリデーションが行われ、臨床現場での使用がFDAによって認可されたものは僅かでした。同市場は、調査研究の活発化により、予測期間を通じて主導権を握ると予測されています。

主要企業や複数の組織による共同研究の増加が市場成長の機会を生み出す

長年の研究の結果、多くの大手メーカーや組織が、プロテオミクスでより多くの知識を得たり、いくつかの病気を治療したりするために、いくつかの製品を開発したり研究したりしており、これがプロテオミクス市場の拡大を促進しています。革新的な創薬のためにプロテオミクスを研究している研究者は、重要な利害関係者がパートナーシップや共同研究を通じてこの分野を成長・発展させているため、大きなチャンスに恵まれています。例えば、プロテオミクスのワークフローは、トランスレーショナルリサーチに加えて、シングルセル研究などのアプリケーションのために、スループット、完全性、品質の面で強化されています。

サーモフィッシャーサイエンティフィック社の2021年11月の発表によると、サーモフィッシャー社は最近、次世代プロテオミクスソリューションのイノベーターであるBiognosys社との共同マーケティング契約を更新しました。このような研究協力は、プロテオミクスの高度な研究を通じて、より良い治療を提供するのに役立つでしょう。

プロテオミクス技術に関連する高コストと限界が市場の成長を妨げる

評価の複雑さ、サンプルの処理方法の一貫性のなさ、重大な偽陽性の可能性、低タンパク質存在量の計算を制限するサンプルのばらつき、解析ソフトウェアの独自性による利用不可能性、シグナルとノイズの間の閾値を決定することの難しさ、厳密な統計的適用の欠如、タンパク質の障害無視、シグナル抑制。

バイオマーカーにおけるプロテオミクスにも限界があり、特にがんにおいては、患者の不均一性がバイオマーカー同定の主な障害の1つであることに言及すべきです。血漿タンパク質の動的多様性が膨大であること、血漿中の重要なバイオマーカーの存在量が限られていること、あるいは患者のばらつきがあることなどが、血漿プロテオミクスを利用したバイオマーカー同定を困難にしています。プロテオミクス技術の発展にもかかわらず、現在の1つの方法では、血漿プロテオームから新しいバイオマーカーを見つける過程で、前述の困難を同時に克服することはまだできません。これらの要素は、市場の拡大を制限する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんのバイオマーカー利用に関する研究件数の増加
      • 技術進歩の拡大
    • 抑制要因
      • プロテオミクス技術に関連する高コストと限界
    • 機会
      • 主要企業または複数の組織による共同研究の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 装置技術別

  • クロマトグラフィー
    • HPLC（高速液体クロマトグラフィー）
    • イオンクロマトグラフィー
    • アフィニティークロマトグラフィー
    • 超臨界流体クロマトグラフィー
  • タンパク質マイクロアレイ
    • バイオチップ
      • ラボオンチップ（マイクロフルイディクス）
      • タンパク質チップ
    • マイクロアレイ装置
      • マイクロアレイスキャナー
      • アレイヤー
  • 分光法
    • 質量分析装置
    • NMR分光法
    • CD分光法
  • 電気泳動
    • ゲル電気泳動
    • キャピラリー電気泳動
  • X線結晶学
  • 表面プラズモン共鳴
  • タンパク質分画
  • その他

第8章 用途別

  • 創薬
  • 臨床診断
  • その他

第9章 サービス・ソフトウェア別

  • バイオインフォマティクスソフトウェア・サービス
    • バイオインフォマティクスサービス
    • バイオインフォマティクスツール
    • バイオインフォマティクスデータベース
  • コアプロテオミクスサービス
    • タンパク質同定サービス
    • タンパク質特性解析サービス
    • 定量的プロテオミクスサービス
    • タンパク質精製サービス
    • タンパク質分離サービス
    • タンパク質シーケンスサービス
    • カスタムアッセイサービス
  • 試薬

第10章 エンドユーザー別

  • 病院
  • 研究所
  • バイオ製薬会社

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Thermo Fisher Scientific Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Danaher
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Merck KGaA
  • Promega Corporation
  • Waters Corporation
  • PerkinElmer Inc.
  • MaxCyte

第14章 付録

目次
Product Code: BT1480

Overview

The proteomics market trends show rising research owing to the rising technological advancements and research studies. Furthermore, rising application for proteomics due to the rising availability of approved instruments and increase in the number of cancer cases in the market, and an increase in the research and development is driving up the proteomics market size.

The market is experiencing a growth in demand for treatment from North America as a result of the rising advancements in this field. With significant competitors like Thermo Fisher Scientific Inc., Danaher, Agilent Technologies, Inc., and Merck KGaA actively operating in the market, the market will grow in upcoming time.

Dynamics

The Growing Number of Research on Biomarkers Usage for Cancer Drive the Growth of the Proteomics Market

Proteomics technology is currently widely applied in molecular medicine, particularly for the identification of biomarkers. Proteomics can find significant disease-specific biomarkers by evaluating a global protein profiling in bodily fluids. By contrasting the protein expression profiles of healthy samples with those affected by disease, expression of proteomics enables the identification of biomarkers. The simplest method for finding biomarkers is 2D-PAGE, in which the protein profiles of healthy and sick samples, including tumor tissues and bodily fluids, are compared.

According to the information they provide, disease-specific biomarkers can be classified as prognostic, diagnostic, and treatment-predictive biomarkers. Proteins that may act as disease-associated biomarkers or be implicated in the course of disease can be found using proteomics. After being discovered by mass spectrometry, biomarkers need to be processed using bioinformatics analysis and replicated in other populations.

Unfortunately, only a few of the biomarkers revealed utilizing proteomics technology were ultimately validated and authorized by the FDA for use in clinical settings despite the increased interest, heavy investigational burdens, and a substantial level of publications. The market is predicted to take the lead throughout the forecast period owing to high research studies.

Rising Collaboration by Key Players or Several Organizations Creates Opportunities for the Growth of the Market

As a result of years of study, a number of major manufacturers or organizations are now developing or studying several products for their usage in proteomics to gain more knowledge and treat several diseases, which is promoting the expansion of the proteomics market. Researchers looking into proteomics for innovative drug discovery have a big opportunity due to the growth and development of the field by important stakeholders through partnerships or collaborations. Proteomics workflows, for instance, have been enhanced in terms of throughput, completeness, and quality for applications like single-cell studies in addition to translational research.

According to a November 2021 announcement from Thermo Fisher Scientific Inc., Thermo Fisher recently renewed their collaborative marketing contract with Biognosys, an innovator of next-generation proteomics solutions, in order to provide laboratories executing high-throughput plasma studies with cutting-edge or streamlined kits, instruments, and software for developing precise and effective workflows at scale. Such research collaborations may help in providing better treatments via high study on proteomics.

The High Cost and Limitations Associated with Proteomic Technology will hamper the growth of the market

The evaluation's complexity, the inconsistent way samples are processed, the potential for significant false positives, the sample's variability restricting the low protein abundance calculation, the analysis software's propriety making it unavailable, the difficulty in determining the threshold between signal and noise, the lack of rigorous statistical application, protein hindrance ignorance, and signal suppression.

Proteomics in biomarker also has its limitations and it should be mentioned that patient heterogeneity is one of the main obstacles to biomarker identification, particularly in cancer. The vast dynamic variety of plasma proteins, limited abundance of important biomarkers in plasma, or patient variability provide difficulties for biomarker identification utilizing plasma proteomics. Despite the development of proteomic techniques, the current one method cannot yet simultaneously overcome the aforementioned difficulties in the process of finding new biomarkers in the plasma proteome. These elements can limit the market's expansion.

Segment Analysis

The global proteomics market is segmented based instrumentation technology, application, services and software, end user and region.

Owing to High Research, the Drug Discovery from Application Segment Accounted for Approximately 56.1% of the Proteomics Market Share

The drug discovery category from application held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in proteomics worldwide. Proteomics research based on MS has increased its influence during the past several years across practically all scientific disciplines. Because finding new drugs is a costly and complex process, newer technologies like proteomics can help and speed up the discovery process. Each new medicine candidate's discovery is thought to cost $70 million.

Drug development involves multiple stages and is a multidisciplinary field that makes use of system biology, genetics, proteomics, and metabolomics. Proteomics is important in the target identification phase. Studies on proteomics are helpful for examining medication activity, toxicity, resistance, and efficacy. Proteomics-based methodologies are more favorable than genomics, despite the fact that genomics is particularly useful in the drug development process, for a number of reasons.

The transcriptome stage is the only one to which genomics can convey biological events, and gene expression profiles are not indicative of protein expression. Therefore, the majority of research focuses on proteomics studies that quantitatively assess proteins and associated post-translational modifications (PTMs).

Geographical Penetration

North America Accounted for Approximately 37.5% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for proteomics in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for application for proteomics.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of diseases, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of proteomics market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various instrumentation technologies and application for proteomics that are being utilized for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the proteomics market include Thermo Fisher Scientific Inc., Danaher, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker, Merck KGaA, Promega Corporation, Waters Corporation, PerkinElmer Inc. and Panacea Biotec among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide proteomics market. The growth of the global proteomics market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Instrumentation Technology

  • Chromatography
    • HPLC
    • Ion Chromatography
    • Affinity Chromatography
    • Supercritical Fluid Chromatography
  • Protein Microarrays
    • Biochips
      • Lab-On-Chips (Microfluidics)
      • Protein Chips
  • Microarray Instruments
    • Microarray Scanners
    • Arrayers
    • Spectroscopy
  • Mass Spectroscopy
  • NMR Spectroscopy
  • CD Spectroscopy
  • Electrophoresis
    • Gel Electrophoresis
    • Capillary Electrophoresis
      • X-Ray Crystallography
      • Surface Plasmon Resonance
      • Protein Fractionation
      • Others

By Application

  • Drug Discovery
  • Clinical Diagnostics
  • Others

By Services and Software

  • Bioinformatics Software and Services
    • Bioinformatics Services
    • Bioinformatics Tools
    • Bioinformatics Databases
  • Core Proteomics Services
    • Protein Identification Services
    • Protein Characterization Services
    • Quantitative Proteomics Services
    • Protein Purification Services
    • Protein Separation Services
    • Protein Sequencing Services
    • Custom Assay Services
  • Reagents

By End User

  • Hospitals
  • Research Laboratories
  • Biopharmaceutical Companies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On June 5, 2023, in conjunction with the introduction of the new timsTOF Ultra mass spectrometer, Bruker Corporation announced transformational sensitivity on its 4D-Proteomics timsTOF platform. It has a brand-new 4th-generation trapped ion mobility separation XR cell, a 14bit digitizer, a new Captive Spray Ionization (CSI) Ultra ion source with a bigger capillary and improved vortex gas flow.
  • On March 7, 2023, proteomics or biopharmaceutical research facilities can now use the latest generation of low-flow HPLC columns from Thermo Fisher Scientific to enhance the separation efficiency and durability of biologically complicated samples. The PAC Neo low-load trapping column, the newest addition to the portfolio, is perfect for the lowest sample sizes in single-cell proteomics separations and has built-in nanoViper connections with Vanquish Neo UHPLC equipment for simplicity of use and decreased chance of errors.
  • On February 17, 2022, Agilent Technologies Inc. acquired cutting-edge artificial intelligence (AI) technology created by Virtual Control, a maker of AI and machine learning software that develops novel analysis methods for laboratory testing. The software, dubbed ACIES, will be incorporated by Agilent into its top-tier gas chromatography with mass spectrometry platforms in order to boost the effectiveness, efficiency, and precision of the high-throughput labs that the business works with all over the world.

DMI Opinion:

The global proteomics market is going to see decent growth in upcoming years owing to rising usage of proteomics and novel instruments/product launches. Several researches are taking place worldwide for treatment of cancer. Numerous advances are taking place leading to the growth of market such as biomarkers. According to DMI the proteomics market will see a decent growth with several novel treatments in the market.

Why Purchase the Report?

  • To visualize the global proteomics market segmentation based on instrumentation technology, application, services and software, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of proteomics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global proteomics market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Instrumentation Technology
  • 3.2. Snippet by Application
  • 3.3. Snippet by Services and Software
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Number of Research on Biomarkers Usage for Cancer
      • 4.1.1.2. Rising Technological Adavancements
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost and Limitations Associated with Proteomic Technology
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Collaboration by Key Players or Several Organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Instrumentation Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 7.1.2. Market Attractiveness Index, By Instrumentation Technology
  • 7.2. Chromatography *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. HPLC
    • 7.2.4. Ion Chromatography
    • 7.2.5. Affinity Chromatography
    • 7.2.6. Supercritical Fluid Chromatography
  • 7.3. Protein Microarrays
    • 7.3.1. Biochips
      • 7.3.1.1. Lab-On-Chips (Microfluidics)
      • 7.3.1.2. Protein Chips
    • 7.3.2. Microarray Instruments
      • 7.3.2.1. Microarray Scanners
      • 7.3.2.2. Arrayers
  • 7.4. Spectroscopy
    • 7.4.1. Mass Spectroscopy
    • 7.4.2. NMR Spectroscopy
    • 7.4.3. CD Spectroscopy
  • 7.5. Electrophoresis
    • 7.5.1. Gel Electrophoresis
    • 7.5.2. Capillary Electrophoresis
  • 7.6. X-Ray Crystallography
  • 7.7. Surface Plasmon Resonance
  • 7.8. Protein Fractionation
  • 7.9. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical Diagnostics
  • 8.4. Others

9. By Services and Software

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 9.1.2. Market Attractiveness Index, By Services and Software
  • 9.2. Bioinformatics Software and Services *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Bioinformatics Services
    • 9.2.4. Bioinformatics Tools
    • 9.2.5. Bioinformatics Databases
  • 9.3. Core Proteomics Services
    • 9.3.1. Protein Identification Services
    • 9.3.2. Protein Characterization Services
    • 9.3.3. Quantitative Proteomics Services
    • 9.3.4. Protein Purification Services
    • 9.3.5. Protein Separation Services
    • 9.3.6. Protein Sequencing Services
    • 9.3.7. Custom Assay Services
  • 9.4. Reagents

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Research Laboratories
  • 10.4. Biopharmaceutical Companies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.5.1. Brazil
      • 12.4.5.2. Argentina
      • 12.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Instrumentation Technology
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services and Software
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc. *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Danaher
  • 13.3. Agilent Technologies, Inc.
  • 13.4. Bio-Rad Laboratories, Inc.
  • 13.5. Bruker
  • 13.6. Merck KGaA
  • 13.7. Promega Corporation
  • 13.8. Waters Corporation
  • 13.9. PerkinElmer Inc.
  • 13.10. MaxCyte

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us